PPAR alpha [peroxisome proliferator-activated receptor-alpha]: A phase 2 dose-finding and safety study for atherogenic dyslipidemia by Eli Lilly

Trial Profile

PPAR alpha [peroxisome proliferator-activated receptor-alpha]: A phase 2 dose-finding and safety study for atherogenic dyslipidemia by Eli Lilly

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Mar 2007

At a glance

  • Drugs LY 518674 (Primary) ; Fenofibrate
  • Indications Hypercholesterolaemia; Lipid metabolism disorders
  • Focus Biomarker; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 25 Mar 2007 Results have been published
    • 06 Dec 2006 Status change
    • 05 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top